Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From PharmaScience

Arès To Lead Up Pharmascience In 2023 After Leaving Sandoz

Martin Arès is to return to his native Canada early in the new year to take the top job at local generics player Pharmascience, after seven years with Sandoz.

Executive Changes Leadership

Indivior Looks To Cement Addiction Drug Leadership With Opiant Buy

Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.

M & A Business Strategies

Cellarity Takes Broader, Whole-Cell Approach To Drug Discovery

CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.

Artificial Intelligence Financing

Pharmascience Faces Six-Year Wait On Canadian Invega Sustenna

Pharmascience has failed in a two-pronged validity challenge to a key patent shielding Janssen’s Invega Sustenna treatment for schizophrenia.

Legal Issues Intellectual Property
See All

Company Information

UsernamePublicRestriction

Register